Compare Microsoft (MSFT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs BIO-TECHNE Corp — how do they compare? Microsoft trades at $502.32 (market cap $3.76T), while BIO-TECHNE Corp trades at $72.06 (market cap $11.24B). The key difference: Microsoft is far larger — about 334.5× BIO-TECHNE Corp's market cap, and Microsoft pays the higher dividend (0.72%). Which is the better fit depends on your goals.
| MSFT | TECH | |
|---|---|---|
Market Cap | $3.76T | $11.24B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $72.29 |
52-Week Low | $352.83 | $43.31 |
Enterprise Value | $3.74T | $11.32B |
Dividend Yield | 0.72% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $501.28, up 0.26% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 forecast. Revenue growth is robust, reaching $281.72 billion in 2025, with a net income margin of 40.31%. Analyst sentiment is overwhelmingly positive, with 80.49% recommending Buy and a consensus price target of $553.70.
The outlook for MSFT remains favorable, driven by AI leadership, Azure cloud momentum, and solid financials. Key risks include elevated capital expenditure concerns and competitive pressures. With a P/E of 28.19, the valuation is premium but supported by growth. Institutional ownership trends and recent dividend actions underscore confidence, though investors should monitor execution on AI investments and macroeconomic headwinds.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
